No surprise. Just another terrible example of the one-sided – potentially harmful – information often disseminated on the network TV morning programs. See the latest review of the CBS Early Show on HealthNewsReview.org
It wraps up a very good week for former tennis star John McEnroe. But not so good for men who may have seen him on TV.
* A prime time appearance on CNN’s Larry King Live promoting prostate cancer screening
* A CBS Early Show appearance promoting prostate cancer screening
And he was getting paid all the time by a drug company – something clearly noted on the website that McEnroe promoted – but something CBS never disclosed on the air.
GlaxoSmithKline funded and helped develop this campaign, including providing compensation to Mr. McEnroe.
CBS merely turned over the network to this drug company sponsored message – a message that has the support of the American Urological Association but that lacks the support of other respected medical organizations such as the American Cancer Society and the US Preventive Services Task Force.
Shameful in its one-sided, imbalanced, incomplete approach, treating McEnroe’s message as gospel.
Opinions on other issues in news, journals, PR, advertising, marketing
Monday at #ADA2021, an infectious disease epidemiologist, a journalist, and a researcher shared perspectives on communication of risk in the era of COVID-19: http://ow.ly/ROfR30rMeE7 @AstleyCM @garyschwitzer @berthahidalgo @ADA_DiabetesPro
Shoutouts to @susan_bewley @drkevinknopf @MichaelBaum11 in this call for more than fawning coverage from press releases for these kinds of stories.
Also, linked history inside goes back 5 years just on Grail apparently trying to become Holy Grail. https://twitter.com/garyschwitzer/status/1408849696416841731
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Marilyn Mann
October 18, 2009 at 11:01 amI’m wondering if under the Federal Trade Commission’s new guidelines, the Glaxo payment would have to be disclosed. See this blog post for a summary and a link to the FTC release:
http://www.experiencetheblog.com/2009/10/10-simple-things-to-know-about-ftcs-new.html
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like